Market Place
Sourcing Support
Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Benefit
11 Dec 2024 //
PRESS RELEASE
Arvinas & Pfizer Present Ph 1b Data on Vepdegestrant at SABCS 2024
10 Dec 2024 //
GLOBENEWSWIRE
Arvinas to Present at Piper Sandler 36th Annual Health Conference
27 Nov 2024 //
GLOBENEWSWIRE
Arvinas`s Vepdegestrant Posters at 2024 San Antonio Symposium
25 Nov 2024 //
GLOBENEWSWIRE
Arvinas to Participate in Upcoming Investor Conferences
04 Nov 2024 //
GLOBENEWSWIRE
Arvinas Reports Q3 2024 Financial Results & Corporate Update
30 Oct 2024 //
GLOBENEWSWIRE
Arvinas Gives Back To Local Greater New Haven Community
22 Oct 2024 //
GLOBENEWSWIRE
Arvinas Reports Q3 2024 Results And Hosts Webcast On October 30
21 Oct 2024 //
GLOBENEWSWIRE
Arvinas to Participate in Upcoming Investor Conferences
29 Aug 2024 //
GLOBENEWSWIRE
Arvinas Reports Q2 2024 Results And Provides Corporate Update
30 Jul 2024 //
GLOBENEWSWIRE
Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer
24 Jun 2024 //
GLOBENEWSWIRE
Arvinas Presentations on PROTAC® Programs Targeting BCL6 and LRRK2
21 Jun 2024 //
GLOBENEWSWIRE
Arvinas Promotes Ian Taylor To President Of Research And Development
17 Jun 2024 //
GLOBENEWSWIRE
Arvinas to Participate in Upcoming Investor Conferences
03 Jun 2024 //
GLOBENEWSWIRE
Arvinas Asco Presentations: Upcoming 2024 Annual Congress Featured
23 May 2024 //
GLOBENEWSWIRE
Arvinas & Pfizer announce updated clinical data from Ph1b Trial of Vepdegestrant
18 May 2024 //
INDINPHARMAPOST
Arvinas, Pfizer Update Vepdegestrant + Palbociclib Phase 1b Data
16 May 2024 //
GLOBENEWSWIRE
Pfizer, Arvinas’ breast cancer drug combo keeps momentum after Phase 1b update
16 May 2024 //
ENDPTS
Arvinas Vepdegestrant Posters At ESMO Breast Cancer Congress 2024
09 May 2024 //
GLOBENEWSWIRE
Arvinas Reports Q1 2024 Financials And Corporate Update
07 May 2024 //
GLOBENEWSWIRE
Arvinas to Present at Upcoming Investor Conferences
02 May 2024 //
GLOBENEWSWIRE
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
24 Apr 2024 //
GLOBENEWSWIRE
Novartis pays $150M for Arvinas` prostate tumor protein degrader
12 Apr 2024 //
FIERCE BIOTECH
Arvinas, Novartis Deal For ARV-766 Prostate Cancer PROTAC®
11 Apr 2024 //
GLOBENEWSWIRE
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
18 Mar 2024 //
GLOBENEWSWIRE
Arvinas to Participate in Upcoming Investor Conferences
04 Mar 2024 //
GLOBENEWSWIRE
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 2024 //
GLOBENEWSWIRE
Arvinas Announces First-in-Human Dosing of ARV-102
20 Feb 2024 //
GLOBENEWSWIRE
Arvinas Announces Chief Financial Officer Transition
20 Feb 2024 //
GLOBENEWSWIRE
Arvinas and Pfizers Vepdegestrant (ARV-471) Receives FDA Fast Track Designation
06 Feb 2024 //
GLOBENEWSWIRE
Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference
01 Feb 2024 //
GLOBENEWSWIRE
Arvinas Appoints Jared Freedberg as General Counsel
16 Jan 2024 //
GLOBENEWSWIRE
Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant
05 Dec 2023 //
GLOBENEWSWIRE
Does Arvinas Have the Potential to Rally 145.52% as Analysts Expect?
01 Dec 2023 //
YAHOO FINANCE
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data
28 Nov 2023 //
GLOBENEWSWIRE
Arvinas gets $350M boost from investors to extend runway into 2027
27 Nov 2023 //
ENDPTS
Arvinas Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Arvinas to Participate in Upcoming Investor Conferences
02 Nov 2023 //
GLOBENEWSWIRE
Potential of Arvinas PROTAC AR Degraders Reinforced by 11.1 months rPFS
22 Oct 2023 //
GLOBENEWSWIRE
Arvinas Gives Back to Local Greater Haven Community in Second Annual Impact Day
18 Oct 2023 //
GLOBENEWSWIRE
Arvinas & Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation
15 Oct 2023 //
GLOBENEWSWIRE
Arvinas Announces Bavdegalutamide Poster Presentation at ESMO Congress 2023
15 Oct 2023 //
GLOBENEWSWIRE
Arvinas to Participate in Upcoming Investor Conferences
01 Sep 2023 //
GLOBENEWSWIRE
Arvinas Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
Arvinas and Pfizer Awarded Innovation Passport Designation for Vepdegestrant
31 Jul 2023 //
GLOBENEWSWIRE
Arvinas Announces Changes to its Board of Directors
15 Jun 2023 //
GLOBENEWSWIRE
Olema, Arvinas spike after analyst remarks on breast cancer drugs
12 Jun 2023 //
TRADING VIEW
Arvinas: Nothing Interesting In The Near Term
12 Jun 2023 //
SEEKING ALPHA
Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation
08 Jun 2023 //
GLOBENEWSWIRE
Arvinas to Participate in Upcoming Investor Conferences
05 Jun 2023 //
GLOBENEWSWIRE
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation
08 May 2023 //
GLOBENEWSWIRE
Arvinas Reports 1Q 2023 Financial Results &Provides Corporate Update
05 May 2023 //
PRESS RELEASE
Arvinas to Present at the Bank of America Securities 2023 Healthcare Conference
03 May 2023 //
GLOBENEWSWIRE
Arvinas and Quantum Leap Healthcare Announce Clinical Study Vepdegestrant
02 May 2023 //
PR NEWSWIRE
Arvinas to Present at Stifel Targeted Oncology Day
21 Apr 2023 //
GLOBENEWSWIRE
Arvinas, Inc. (ARVN) Surges 7.6%: Is This an Indication of Further Gains?
14 Apr 2023 //
FINANCE YAHOO
Arvinas Appoints Kelly Page as Senior Vice President, Global Head of Oncology Strategy and Program Leadership
03 Apr 2023 //
PRESS RELEASE
Arvinas to Participate in Upcoming Investor Conferences
27 Feb 2023 //
GLOBENEWSWIRE
Arvinas Reports Fourth Quarter and Full Year 2022 Financial Results
23 Feb 2023 //
GLOBENEWSWIRE
Arvinas founder snags $76M for next bet, Halda Therapeutics
14 Feb 2023 //
ENDPTS
